Evolus Shares Rise on Jump in Revenue

Dow Jones

2025/01/21

By Don Nico Forbes

Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance.

Shares were up 16% in premarket trading at $12.20.

The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.

"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva," said Chief Executive David Moatazedi.

Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results.

The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days.

Write to Don Nico Forbes at don.forbes@wsj.com

(END) Dow Jones Newswires

January 21, 2025 09:12 ET (14:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2505276857"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505276857\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505276857?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505276857","market":"fut","top_or_hot":-1,"title":"Evolus Shares Rise on Jump in Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n</p>\n<p>\n  Shares were up 16% in premarket trading at $12.20. \n</p>\n<p>\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n</p>\n<p>\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n</p>\n<p>\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n</p>\n<p>\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 09:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus Shares Rise on Jump in Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus Shares Rise on Jump in Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-21 22:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Don Nico Forbes \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n</p>\n<p>\n  Shares were up 16% in premarket trading at $12.20. \n</p>\n<p>\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n</p>\n<p>\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n</p>\n<p>\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n</p>\n<p>\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Don Nico Forbes at don.forbes@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 09:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505276857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505276857","pubTimestamp":1737468720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance.Shares were up 16% in premarket trading at $12.20.The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million.\"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi.Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results.The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form a","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc."},"translate_title":"Evolus股价因收入增长而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":0.9},"content_text":"By Don Nico Forbes \n\n\n \n\n\n  Shares in Evolus rose after the company reported a jump in revenue for the fourth quarter and full year, topping company guidance. \n\n\n  Shares were up 16% in premarket trading at $12.20. \n\n\n  The pharmaceutical company reported revenue of $79.0 million for the quarter, up 30% compared with the prior-year quarter. For 2024, revenue was $266.3 million, up 32% and meeting company guidance of between $260 million and $266 million. \n\n\n  \"The preliminary results for the fourth quarter and full-year 2024 underscore the strength of our operational execution and significant market share gains, driven by deeper penetration of the U.S. neurotoxin market with Jeuveau and international expansion of Nuceiva,\" said Chief Executive David Moatazedi. \n\n\n  Looking ahead, Evolus said it expects revenue of $345 million to $355 million in 2025, representing growth of 30% to 33% compared with preliminary 2024 results. \n\n\n  The company added that it expects to receive approval from the U.S. Food and Drug Administration for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels within the next 90 days. \n\n\n \n\n\n  Write to Don Nico Forbes at don.forbes@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2025 09:12 ET (14:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}